01:21 · 11 āļāļļāļĄāļ āļēāļžāļąāļ™āļ˜āđŒ 2025

Springworks Therapeutics surges 36% amid acquisition speculation by Merck 🔎📈

Merck KGaA (MRCG.DE), the German healthcare and technology company, is in advanced negotiations to acquire U.S.-based Springworks Therapeutics (SWTX.US), a biotech firm specializing in cancer and rare disease treatments. According to sources familiar with the matter, a deal could be finalized in the coming weeks, although terms of the potential agreement have not been disclosed.

Following the news, Springworks' stock surged almost 40% before stabilizing at a 36% gain, reflecting strong investor interest. Springworks, which has a market capitalization of approximately $4 billion, has developed Ogsiveo, a monotherapy drug approved in the U.S. for the treatment of desmoid tumors. The potential acquisition would strengthen Merck's oncology pipeline.

Uncertain Outcome and Industry Interest

While negotiations between Merck and Springworks have progressed, sources caution that other potential buyers may still emerge. Springworks has previously been the subject of takeover speculation, with reports last year suggesting interest from Swiss pharmaceutical firms and AbbVie (ABBV.US).

Merck declined to comment on the discussions but stated that it "continuously assesses options that could support its businesses and strategic positioning." Springworks has also declined to provide a statement regarding the potential deal.

āļĢāļąāļš Welcome Bonus 10% āđ€āļĄāļ·āđˆāļ­āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļāļąāļš XTB

āļĢāļąāļš Welcome Bonus 10% āđ€āļĄāļ·āđˆāļ­āđ€āļĢāļīāđˆāļĄāđ€āļ—āļĢāļ”āļāļąāļš XTB

āđ€āļĢāļīāđˆāļĄāļ•āđ‰āļ™āļ‡āđˆāļēāļĒ āđ† āđ€āļžāļĩāļĒāļ‡āđ€āļ›āļīāļ”āļšāļąāļāļŠāļĩāđāļĨāļ°āļāļēāļāđ€āļ‡āļīāļ™āļ„āļĢāļąāđ‰āļ‡āđāļĢāļ āļāđ‡āļĢāļąāļšāđ‚āļšāļ™āļąāļŠāļŠāļđāļ‡āļŠāļļāļ” 10 USD āđ€āļ‚āđ‰āļēāļšāļąāļāļŠāļĩāđ€āļ—āļĢāļ”āļ‚āļ­āļ‡āļ„āļļāļ“āđ‚āļ”āļĒāļ•āļĢāļ‡ āļžāļĢāđ‰āļ­āļĄāđ€āļ—āļĢāļ” āļŸāļ­āđ€āļĢāđ‡āļāļ‹āđŒ āļ—āļ­āļ‡āļ„āļģ āļ”āļąāļŠāļ™āļĩāđāļĨāļ°āļŠāļīāļ™āļ—āļĢāļąāļžāļĒāđŒāļ­āļ·āđˆāļ™ āđ†Â āļ­āļĩāļāļĄāļēāļāļĄāļēāļĒ 

āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10% āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10% āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10% āļĢāļąāļšāđ‚āļšāļ™āļąāļŠ 10%
20 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 22:57

Wall Street āļĢāđˆāļ§āļ‡āļŦāļ™āļąāļāđ€āļ›āđ‡āļ™āļŠāļĩāđāļ”āļ‡

20 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 16:14

ECB āđ€āļ•āļ·āļ­āļ™āļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡āļŸāļ­āļ‡āļŠāļšāļđāđˆ AI āļˆāļēāļāļāļĢāļ°āđāļŠ IPO āđāļĨāļ°āļŦāļ™āļĩāđ‰āļĄāļŦāļēāļĻāļēāļĨāļ‚āļ­āļ‡ Big Tech

20 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 14:03

āļ”āļąāļŠāļ™āļĩāļŦāļļāđ‰āļ™āđāļĨāļ°āđ‚āļĨāļŦāļ°āļĒāļąāļ‡āļ„āļ‡āļ›āļĢāļąāļšāļ•āļąāļ§āļĨāļ”āļĨāļ‡ ðŸ“‰

20 āļžāļĪāļĻāļˆāļīāļāļēāļĒāļ™ 2026, 09:04

Anthropic āđ€āļ›āļīāļ”āļ•āļĨāļēāļ”āđāļĢāļ‡ āđāļ•āđˆāļāļ§āđˆāļēāļˆāļ°āļ›āļīāļ”āļ§āļąāļ™ āļŠāđˆāļ§āļ™āļ•āđˆāļēāļ‡āļŦāļēāļĒāđ„āļ›āļ„āļĢāļķāđˆāļ‡āļŦāļ™āļķāđˆāļ‡ āđāļĨāļ°āļ•āļĨāļēāļ”āļ—āļąāđ‰āļ‡āļāļĢāļ°āļ”āļēāļ™āļāđ‡āđ„āļĄāđˆāđ„āļ”āđ‰āļĢāđˆāļ§āļ‡āļ‰āļĨāļ­āļ‡āļ”āđ‰āļ§āļĒ

āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ—āļĩāđˆāđ€āļĢāļēāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļĄāļĩāļ„āļ§āļēāļĄāđ€āļŠāļĩāđˆāļĒāļ‡ āđ€āļĻāļĐāļŦāļļāđ‰āļ™ (Fractional Shares) āđ€āļ›āđ‡āļ™āļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļĩāđˆāđƒāļŦāđ‰āļšāļĢāļīāļāļēāļĢāļˆāļēāļ XTB āđāļŠāļ”āļ‡āļ–āļķāļ‡āļāļēāļĢāđ€āļ›āđ‡āļ™āđ€āļˆāđ‰āļēāļ‚āļ­āļ‡āļŦāļļāđ‰āļ™āļšāļēāļ‡āļŠāđˆāļ§āļ™āļŦāļĢāļ·āļ­ ETF āđ€āļĻāļĐāļŦāļļāđ‰āļ™āđ„āļĄāđˆāđƒāļŠāđˆāļœāļĨāļīāļ•āļ āļąāļ“āļ‘āđŒāļ—āļēāļ‡āļāļēāļĢāđ€āļ‡āļīāļ™āļ­āļīāļŠāļĢāļ° āļŠāļīāļ—āļ˜āļīāļ‚āļ­āļ‡āļœāļđāđ‰āļ–āļ·āļ­āļŦāļļāđ‰āļ™āļ­āļēāļˆāļ–āļđāļāļˆāļģāļāļąāļ”
āļ„āļ§āļēāļĄāļŠāļđāļāđ€āļŠāļĩāļĒāļŠāļēāļĄāļēāļĢāļ–āđ€āļāļīāļ™āļāļ§āđˆāļēāđ€āļ‡āļīāļ™āļ—āļĩāđˆāļāļēāļ